News & Media

Signal

Admedus appoints new public relations consultancy

16, February, 2017

Posted In: Featured

Admedus Limited (Admedus) today announced that Signal Leadership Communication Inc. (Signal) of Toronto has been appointed as its new public relations firm. Signal Principal Bob Pickard will personally serve as corporate communication counsel for Admedus. Read the full Company announcement here.

> Read more

admin-ajax

The VascuCel bio-scaffold: next-generation tissue engineering

18, November, 2016

Posted In: Blog

Advances in tissue engineering have led Admedus to the development of VascuCel, a pure collagen scaffold specifically designed to provide an all-in-one solution to current patching solutions. Read the full Admeus VascuCel Review here.

> Read more

8-year-no-calcification

CardioCel: 8 years on and still free from calcification

23, August, 2016

Posted In: Featured, Blog

CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]

> Read more

Clinical-applications-image-e1458790304767

Long-term CardioCel study shows no evidence of calcification after 8 years

22, August, 2016

Posted In: Uncategorized

Admedus Limited (ASX: AHZ) has today announced positive long-term data from its Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel. All patients continue to progress well, with no sign of calcification after 8 years or need for repeat procedures. Read the full Company announcement here.

> Read more

Cardiovascular News

Long-term study indicates no calcification with CardioCel after eight years

22, August, 2016

Posted In: In the media

Long-term data from a Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel shows that all patients continue to progress well, with no sign of calcification or need for repeat procedures.

> Read more

Admedus Investor Presentation – July 2016

26, July, 2016

Posted In: Videos

> Watch the video

02_NoCircle

Using the ADAPT engineering process to create durable tissue scaffolds

8, July, 2016

Posted In: Featured, Blog

Admedus is an Australian-based healthcare company leading the world in regenerative medicine and tissue engineering research. Using its proprietary ADAPT® tissue engineering technology, Admedus can transform xenograft (animal) tissue into durable bio-scaffolds that can be used for soft tissue repair within patients. The medical technology was first brought to Australia over 20 years ago by […]

> Read more

Danny-Zanardo-2

Admedus a major distributor of infusion solutions

10, June, 2016

Posted In: Blog

Many people would have heard about the great work Admedus is doing in the field of tissue engineering and immunotherapies, but fewer people would know that Admedus is also a major distributor of infusion solutions (intravenous products and infusion pumps) to hospitals in Australia and New Zealand. The highly successful infusion portfolio has been part […]

> Read more

mass device logo

Admedus shares rise on hospital infusion pump supply deal with Arcomed

25, May, 2016

Posted In: In the media, Featured

Admedus said today it won a supply contract with the new Royal Adelaide Hospital for the installation of the Arcomed chroma infusion pump systems. The supply tender includes ongoing technical and clinical support as well as consumable products for the systems over the next 5 years.

> Read more

Manufacturing-Award

Admedus Wins 2016 Australian Manufacturer of the Year Award

14, May, 2016

Posted In: In the media, Featured

After triumphing in the Most Innovative category, Admedus also took out the night’s biggest award ‘Manufacturer of the Year’. In August 2014 Admedus opened its state-of-the-art bio-manufacturing facility in Malaga, WA, and has experienced huge success in exporting its bio-scaffold regenerative medicine product, CardioCel, since then.

> Read more

Admedus Investor Presentation – May 2016

5, May, 2016

Posted In: Videos

> Watch the video

Julian 2

A day with Europe’s leading cardiovascular surgeons

5, May, 2016

Posted In: Blog

In April, I had the privilege of spending the day with over forty of Europe’s leading cardiovascular surgeons. The purpose – an Admedus workshop to discuss the use of CardioCel to reconstruct heart valves and its potential in the future treatment of heart valve disease. Held in Amsterdam, the experts meeting shed light on the critical issues and […]

> Read more

david rhodes smallv2

Are all cardiovascular tissue patches the same?

5, April, 2016

Posted In: Blog

While some people may claim that all cardiovascular tissue patches (pericardial patches/bioscaffolds) are fundamentally the same, we know this is not the case. Surgeons and patients alike are searching for a bioscaffold that is safe, strong and durable. More specifically, they want a material that doesn’t calcify (harden) at the site of surgery and can […]

> Read more

Channel 7 News – A world first treatment for HPV

22, March, 2016

Posted In: Videos, In the media

> Watch the video

The Australian Logo

Admedus HSV-2 clinical results encouraging – Morgans

7, March, 2016

Posted In: In the media, Featured

Morgans healthcare analyst Scott Power talks to The Australian about Admedus’s HSV-2 Phase II clinical trial results.

> Read more

Julian 2

Partnering in the healthcare industry

7, March, 2016

Posted In: Blog

Recently we had the pleasure of presenting at BioMelbourne Network’s Health Technology Partnering Forum ‘Collaborate to Innovate: Approaches to Partnering’ in Melbourne. During the event a range of industry experts from Johnson & Johnson, Pfizer, Acrux, Hatchtech, University of Melbourne, GBS Venture Partners and Admedus all shared their views on the best approaches to partnering and […]

> Read more

huffington post

Gardasil creator is testing a DNA vaccine to wipe out cancer-causing HPV virus

1, March, 2016

Posted In: In the media

Professor Ian Frazer (the creator of Gardasil) is working with healthcare company Admedus to create a DNA vaccine which could be injected in people who already have HPV to stop it progressing to cervical cancer. Admedus Chief Scientific Officer Dr David Rhodes said the technology developed by Admedus in conjunction with Frazer could potentially be applied to a […]

> Read more

Repair7

Performance and versatility of a new tissue engineered collagen scaffold in cardiovascular surgery

24, February, 2016

Posted In: In the media

Professor Leon Neethling was published in the February 2016 edition of Pädiatrische Kardiologie (German Pediatric Cardiology) journal where he discussed the performance and versatility of CardioCel in cardiovascular surgery. First publication: Lebendige Wissenschaft, Spitzenforschung Pädiatrische Kardiologie 2016; 96-466:46-47 Posted here with kind permission of Alpha Informationsgesellschaft mbH, Germany

> Read more

Admedus AGM 2015 – Mr Lee Rodne

15, February, 2016

Posted In: Videos

> Watch the video

david rhodes smallv2

Admedus next generation vaccine technology targets HPV

12, February, 2016

Posted In: Blog

2016 is looking to be an important year for Admedus as our immunotherapy programs continue to progress well. Working with Professor Ian Frazer and his team, we are developing therapeutic vaccines to target human papillomavirus (HPV) and herpes simplex virus 2 (HSV-2). These vaccines address significant diseases with a huge unmet medical need and if successful, […]

> Read more

Wayne-Paterson-Web

Open Letter From Mr Wayne Paterson To Shareholders

10, February, 2016

Posted In: Uncategorized

Dear Shareholders and friends of Admedus, I would like to take the opportunity to update you on current events and what you can expect from the team moving forward.

> Read more

mass device logo

Admedus inks exclusive distro deal with Coroneo

27, January, 2016

Posted In: In the media

Admedus (ASX:AHZ) has inked an exclusive distribution agreement with Coroneo to sell its extra aortic annuloplasty ring and other heart valve surgery instruments in Germany and the U.K.

> Read more

Julian 2

Reconstructing valves vs replacing them?

7, January, 2016

Posted In: Blog

In our last blog, we discussed the current tendency by surgeons to turn to valve replacements for aortic valve repair, rather than reconstructing the valve, even though replacement options are associated with sub-optimal outcomes. The use of replacements is partly due to the fact that surgeons did not have a tissue scaffold to reconstruct the […]

> Read more

Julian 2

Reconstructing the aortic valve using CardioCel®

1, December, 2015

Posted In: Blog

Aortic valve disease is the most common cardiac anomaly and is often associated with leaflet defects. Traditionally, aortic valves have been replaced with a bio-prosthetic or mechanical heart valve, even though these replacement methods were associated with suboptimal outcomes such as calcification resulting in re-operation. While far from the optimal choice, the need to use […]

> Read more

david rhodes smallv2

World Health Organisation: You probably have herpes

6, November, 2015

Posted In: Blog

“We really need to accelerate the development of vaccines against herpes simplex virus.” Sami Gottlieb, WHO medical officer. Figures released by the World Health Organisation (WHO) last week stated that 417 million people in the age group 15-49 age group are living with HSV-2. The recent estimates highlight not only the significance of this virus, […]

> Read more

Cardiovascular News

CardioCel bio-scaffold launched and sold in Malaysia

4, November, 2015

Posted In: In the media, Featured

CardioCel has now been launched in Malaysia and the Company has achieved its first sales in the country.

> Read more

Admedus Investor Presentation – October 2015

30, October, 2015

Posted In: Videos

> Watch the video

TESTING-SAMPLES_RESIZED

Welcome to the Admedus blog

29, October, 2015

Posted In: Blog

It gives me great pleasure to announce the launch of the Admedus blog. Information is an important aspect of the specialist healthcare service we provide. Whether it’s information about the range of medical devices Admedus has on market or those projects in development, to healthcare providers or for investors. Quality communication and engagement with our […]

> Read more

biotuesday

Admedus HSV-2 vaccine set for key value inflection point

22, September, 2015

Posted In: In the media

In an interview with leading online biotech site, BioTuesdays, Chief Operating Officer Julian Chick discusses Admedus’ anticipated interim results from a Phase 2 trial of its therapeutic vaccine for the treatment of herpes simplex virus-2 (HSV-2).

> Read more

mass device logo

Down-under medtech firm Admedus looks to future in bio-scaffolds

11, September, 2015

Posted In: In the media

Admedus Chief Operating Officer Julian Chick spoke to MassDevice.com about the Company’s flagship product CardioCel, how it’s using bio-scaffolds to grow in the cardiac repair market and where it’s looking to take bio-scaffolds next.

> Read more

Ausbio

Biotech’s role in advanced manufacturing

5, September, 2015

Posted In: In the media, Featured

With an increase in Australian biotech companies moving their manufacturing off-shore, there has been a call for the Government to further support the sector through better R&D and tax incentives. Admedus Chief Operating Officer, Dr Julian Chick, discusses biotech’s role in advanced manufacturing in Australia and the work Admedus is doing at its state of the […]

> Read more

Welcome to ADMEDUS

16, February, 2015

Posted In: Videos

Admedus is a unique, innovative and diversified, global healthcare company.

> Watch the video

ADMEDUS Immunotherapies

13, February, 2015

Posted In: Videos

> Watch the video

ADMEDUS Tissue Engineering

12, February, 2015

Posted In: Videos

Technology which helps the human body to repair and heal itself.

> Watch the video

ADMEDUS Medical Products

12, February, 2015

Posted In: Videos

Admedus specialises in infusion products and devices that provide cost-efficient solutions for hospitals

> Watch the video

Professor Ian Frazer | ADMEDUS Immunotherapies

14, October, 2014

Posted In: Videos

Professor Ian Frazer discusses Admedus Immunotherapies and his team's research.

> Watch the video

Admedus officially opens new Bio-manufacturing facility

10, October, 2014

Posted In: Videos

> Watch the video

Channel 10 – Taking Heart

20, August, 2014

Posted In: Videos

> Watch the video

Southern Cross Tasmania – Treatment of Heart Defects

20, August, 2014

Posted In: Videos

> Watch the video

Channel 9 – Heart Patch Saving Tiny Lives

20, August, 2014

Posted In: Videos

> Watch the video

Channel 7 – Bio-Manufacturing Facility Malaga Launch

20, August, 2014

Posted In: Videos

> Watch the video

How CardioCel® Works in the Human Heart

5, May, 2014

Posted In: Videos

A short animation demonstrating how CardioCel® is used to repair defects in the human heart.

> Watch the video

Saving Young Lives

13, September, 2013

Posted In: Videos

Channel 7 Brisbane - Babies with heart defects treated with CardioCel®

> Watch the video

World First Technology to Save Babies

13, September, 2013

Posted In: Videos

Channel 9 National News - saving babies using the CardioCel® heart patch

> Watch the video

Sky News Australia

2, September, 2013

Posted In: Videos

> Watch the video